Navigation Links
Multiple Vimpat(R) (lacosamide) Studies Presented at American Epilepsy Society Annual Meeting
Date:12/8/2008

8 days required by the inclusion criteria.

A total of 87 percent of patients in the placebo group completed treatment, as did 82 percent, 77 percent, and 62 percent in the 200, 400, and 600 mg/day Vimpat(R) groups.

Summary of Vimpat(R) Data Presented at 2008 AES Annual Meeting

Early Onset of Efficacy in the Initial Weeks of Treatment with Lacosamide: A Pooled Analysis of Three Phase II/III Trials

This analysis found that Vimpat(R) demonstrated statistically significant efficacy as early as the first week of treatment, with consistently significant results for both primary endpoints starting at doses of 100 mg/day.

-- At the end of the first week of treatment in this study, when all participants in the active treatment groups were receiving 100 mg/day of Vimpat(R), a significant reduction in seizure frequency was observed versus placebo (33.0 percent Vimpat(R) group vs. 19.4 percent placebo; p<.01). Also during the first week, 39.1 percent of patients treated with Vimpat(R) experienced a 50 percent or greater reduction in seizures, compared with 31.3 percent in the placebo group (p<.01).

-- By the end of the second week of treatment, when all participants in the treatment groups were receiving 200 mg/day of Vimpat(R), a significant reduction in seizure frequency was observed versus placebo (34.0 percent Vimpat(R) group vs. 20.0 percent placebo; p<.01). The percentage of patients with a 50 percent or greater reduction in seizure frequency was 40.2% for patients receiving Vimpat(R) and 32.2 percent for placebo (p<.01 vs. placebo).

-- These significant seizure reductions appeared to be maintained over subsequent weeks of Vimpat(R) treatment.


    Poster Session 3, December 8, 2008, 8:00 - 9:00 am (Poster 3.256)
    Michael Sperling, MD, David Rudd, PharmD, David Hebert, PhD, Pamela Doty,
     PhD
    Thomas Jefferson Universit
'/>"/>
SOURCE UCB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Genomic Health to Present Multiple New Studies at 31st Annual San Antonio Breast Cancer Symposium
2. Derma Sciences Announces Multiple Clinical Posters Featuring MEDIHONEY(R) and ALGICELL Ag(R) to be Presented at Upcoming Wound Care Conference
3. TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
4. Senescos Preclinical Multiple Myeloma Data to be Presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
5. Bolder BioTechnology Receives $1.6 million NIH Grant to Continue Development of Multiple Sclerosis Drug
6. Environmental Tectonics Corporation Announces a Multiple Sale of Hyperbaric Monoplace Chambers to Comprehensive Healthcare Solutions
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
9. Orexigen Therapeutics Announces Multiple Data Presentations at The Obesity Society Annual Scientific Meeting
10. Memory Pharmaceuticals Completes Phase 1 Multiple Ascending Dose Study of R4996/MEM 63908
11. Environmental Tectonics Corporation Announces a Multiple Sale for Monoplace Hyperbaric Chambers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... MA (PRWEB) January 22, 2015 zFlo ... is pleased to announce an exciting product from a new ... motion analysis solutions over the past 15 years, with offerings ... Most recently, their 3D IMU system (inertial measurement unit), iSen, ...
(Date:1/22/2015)... 2015 Selexis SA, a serial innovation ... Banks (RCBs) used for drug discovery to commercial manufacturing, ... include Next-Generation Sequencing (NGS) data packages. The ... manufacturing by ensuring the integrity of the gene, validation ...
(Date:1/22/2015)... Jan. 22, 2015   Cypher Genomics, Inc., ... (NASDAQ: SQNM ), the leading molecular ... next generation noninvasive prenatal tests (NIPT). Through this ... called Mantis™, to advance analysis of clinically-relevant fetal ...
(Date:1/22/2015)...  Derma Sciences, Inc. (Nasdaq: DSCI ), ... care, announces that AMNIOEXCEL® and AMNIOMATRIX®, amniotic allografts ... the Premier, Inc. Regenerative Skin Grafting contract portfolio. ... and AMNIOMATRIX® product lines, which continue to be ...
Breaking Biology Technology:3D Motion Capture Just Got Easy 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5
... LIVERPOOL, February 2 Gray Healthcare has ... to lead its,expanding Community Recovery Team, as Clinical Director. ... years, experience of senior management in mental,health in both the ... of operations at Cambian Healthcare, covering 12 psychiatric,rehabilitation hospitals, he ...
... SAN DIEGO , Feb. 1 BioMed Realty Trust, Inc. ... its fourth quarter and year ended December 31, 2009 after ... Alan D. Gold , Chairman and Chief Executive Officer, and ... conference call at 10:00 a.m. Pacific Time on Thursday, ...
... Astrogenetix ... Space Station (ISS) to 2020 or beyond. , ... (Vocus) February 1, 2010 -- Astrogenetix is issuing the following statement applauding ... beyond. , ,Thomas B. Pickens III, Chairman of Astrogenetix, Inc.:, , ,“We are excited to ...
Cached Biology Technology:Noel Tracey to Head Up Gray Healthcare Recovery Team 2BioMed Realty Trust to Report 2009 Fourth Quarter and Year-End Results 2Astrogenetix Statement On Nasa's Fiscal Year 2011 Budget Announcement 2
(Date:12/17/2014)... Dec. 16, 2014 Valencell, a leader in performance ... technology to industry leaders such as Intel, Jabra, Atlas, ... biometric wearable products. These products will be showcased at ... Las Vegas . "Our partners ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of the ... to their offering. One major trend ... continuous advances in technology, it is important to upgrade ...
(Date:12/10/2014)... YORK , Dec. 8, 2014 You,ve been here before: ... can,t remember your password, site key or the answer to your ... teacher? Today, Hoyos Labs , a digital ... put an end to the frustration that comes with usernames, passwords ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... existed in the Amazon before the arrival of Europeans, ... the result of research led by Crystal McMichael and ... The finding overturns the idea the Amazon was a ... that transformed vast tracts of the landscape. The ...
... vegetarian and ecological products, but is it really making ... about ethical trade, Gothenburg researchers Bengt Brlde and ... help ease people,s bad conscience, it does nothing to ... fixing the problem will require collective solutions, such as ...
... UC Santa Barbara scientists turned to the simple sponge to ... and found that, but for a mechanism that coordinates the ... synapses, sponges and the rest of the animal world may ... of a protosynaptic gene expression network," are published in the ...
Cached Biology News:Scientists reconstruct pre-Columbian human effects on the Amazon Basin 2Ethical trade: 'Good intentions go to waste' 2Clues to nervous system evolution found in nerve-less sponge 2
... Polyclonal Phosphorylated Anti-GluR1 Glutamate is the ... many years it had been considered to ... NMDA, AMPA and kainate receptors that are ... Recently, glutamate has been shown to regulate ...
Anti-ADP-Ribosylation Factor 1, clone 3F1 Immunogen: Synthetic peptide corresponding to the C-terminal amino acid sequence of human ARF1. Available Date: 38495...
TNF-Related Apoptosis Inducing Ligand-Receptor-1...
Pim-1 (12H8)...
Biology Products: